Clinical Trials Logo

Filter by:
NCT ID: NCT05763589 Recruiting - Child Development Clinical Trials

Study of the Effects of Soy Exposure in Early Life on Bone Development and Gut Microbiota

Start date: December 16, 2022
Phase:
Study type: Observational

In this project, the investigators aim to investigate the effects of soy consumption at early life on the development of gut microbiota and bone growth. The hypothesis to be tested is that early-life exposure to soy optimize bone growth via the alteration of gut microbiota composition. Clinical samples from mother-child pairs recruited into the SMART Gen Hong Kong cohort will be used to examine the association between maternal soy intake with infant gut microbiota and child's bone development. Primary outcome: Bone mineral density; dynamic bone formation parameters; messenger ribonucleic acid (mRNA) expression of bone markers. Secondary outcome: Gut microbiome profile; metabolomic profile in serum, urine or feces; correlation between soy-induced gut microbiota or metabolites and bone growth. The investigators expect that early life exposure to soy will improve bone growth via gut microbiota and provide scientific evidences for the use of soy preparation in early life as a preventive measure for optimizing bone health.

NCT ID: NCT05763147 Recruiting - Clinical trials for Effectiveness and Safety of Pre-filled Flush Syringe

Study of BD Pre-filled Flush Syringes in China

Start date: November 3, 2022
Phase: N/A
Study type: Interventional

This study is to compare the BD PosiFlush™ Pre-filled Flush Syringes (manufactured by BD, USA) and evaluate the effectiveness and safety of the pre-filled flush syringes (manufactured by Suzhou Becton Dickinson Medical Devices Co., Ltd.) for locking and flushing the end of catheter line in Chinese popluation.

NCT ID: NCT05762900 Recruiting - Breast Cancer Clinical Trials

Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients

UNIQUE
Start date: October 25, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II study to investigate the feasibility of Ultra-hypofractionated radiotherapy with or without simultaneous integrated boost for low risk breast cancer patients who have received breast conservative surgery of mastectomy.

NCT ID: NCT05762692 Recruiting - Deep Sedation Clinical Trials

High-flow Nasal Oxygenation During Deep Sedation in Pediatric Dental Patients

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

It is important to choose an appropriate oxygenation technique during intravenous deep sedation in pediatric dental treatment. The study is to evaluate the efficacy and safety of high-flow nasal oxygenation in intravenous deep sedation in pediatric dental patients.

NCT ID: NCT05762510 Recruiting - Clinical trials for Transfusion Dependent Beta-Thalassemia

A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]

Start date: February 22, 2023
Phase: Early Phase 1
Study type: Interventional

This is a single-arm, open label, single-dose study in subjects with transfusion dependent β-thalassaemia. The study will evaluate the safety and efficacy of autologous CD34+ Human Hematopoietic Stem Cells that was transduced with LentiRed Lentivrial vector.

NCT ID: NCT05762094 Recruiting - Clinical trials for Bacterial Infections

A Retrospective Study on Personalized Dosing Strategy of Patients Treated by Carbapenems: 2018-2021

Start date: March 2023
Phase:
Study type: Observational

Patients may benefit from the personalized carbapenem dosing strategy based on pharmacokinetics. The objective of this study is to retrospectively review and analyze the clinical outcomes of patients with different dosing strategy.

NCT ID: NCT05762029 Recruiting - Clinical trials for Extracorporeal Membrane Oxygenation

Treatment of Extracorporeal Membrane Oxygenation in Severe Poisoning

Start date: November 26, 2022
Phase:
Study type: Observational

This is a prospective, multicentre clinical study to determine the value of the Extracorporeal Membrane Oxygenation in the treatment of critically ill poisoning patients and whether there are significant differences in the prognosis of different types or doses of poison/drug poisoning. These conclusions may guide us on how to correctly perform Extracorporeal Membrane Oxygenation, including whether or when should this treatment enabled, the mode of Extracorporeal Membrane Oxygenation, whether to combine blood purification, treatment schedule and disembarkation time.

NCT ID: NCT05761938 Recruiting - Glomerulonephritis Clinical Trials

A Study of Rituximab in Frontline Therapy for Glomerulonephritis

Start date: February 1, 2023
Phase:
Study type: Observational

This study included patients with glomerulonephritis who planned to receive rituximab treatment, and observed the efficacy and safety of rituximab in different glomerulonephritis in the real world. According to the pathological types of glomerulonephritis, they were divided into two cohorts : membranous nephropathy ( MN ) group or minimal change disease / focal segmental glomerulosclerosis ( MCD / FSGS ) group.

NCT ID: NCT05761821 Recruiting - Clinical trials for Complication of Surgical Procedure

Key Factors of Leadless Pacemaker Implantation With Implantation Site, Complications and Prognosis

Start date: October 1, 2022
Phase:
Study type: Observational

To investigate the relationship between key variables in leadless pacemaker implantation with implantation site, intraoperative complications and prognosis.

NCT ID: NCT05761704 Recruiting - Clinical trials for Non-valvular Atrial Fibrillation

Exploratory Observation of Two Short-term Regimens After LAA Occlusion by LAMax LAAC® Device for Subjects With Non-valvular Atrial Fibrillation

Start date: November 16, 2023
Phase: N/A
Study type: Interventional

This is a prospective, single-center, randomized, exploratory clinical observation to explore the overall benefit of short-term dual antiplatelet or novel oral anticoagulant regimens after left atrial appendage (LAA) occlusion by LAMax LAAC® occluder for subjects with non-valvular atrial fibrillation (AF), which will provide a basis for subsequent research on real-world safety and efficacy of LAA closure (LAAC).